Expired activity
Please go to the PowerPak
homepage and select a course.
HEPATORENAL SYNDROME: THE IMPORTANT ROLE OF PHARMACISTS IN IMPROVING
PATIENT OUTCOMES
This educational activity is sponsored by Postgraduate Healthcare
Education, LLC (PHE)
and supported by an educational grant from Mallinckrodt.
FACULTY
Janna Afanasjeva PharmD, BCPS
Clinical Assistant Professor
University of Illinois at Chicago
Drug Information Group
FINANCIAL DISCLOSURE
Janna Afanasjeva PharmD, BCPS has no actual or potential conflicts of
interest in relation to this program.
The clinical reviewer, Ty Kiser, PharmD, has no actual or potential
conflicts of interest in relation to this program.
Susanne Batesko, RN, BSN, and Robin Carrino, as well as the planners,
managers, and other individuals, not previously disclosed, who are in a
position to control the content of Postgraduate Healthcare Education (PHE)
continuing education activities hereby state that they have no relevant
conflicts of interest and no financial relationships or relationships to
products or devices during the past 12 months to disclose in relation to
this activity. PHE is committed to providing participants with a quality
learning experience and to improve clinical outcomes without promoting the
financial interests of a proprietary business.
ACCREDITATION STATEMENTS
PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN:
0430-0000-20-012-H01-P
Credits:
2.0 hours (0.20 ceu)
Type of Activity:
Knowledge
Media:
Internet
Fee Information:
There is no fee for this educational activity.
Estimated time to complete activity:
120 minutes
Published
February 18, 2020
Expires
February 18, 2021
TARGET AUDIENCE
This accredited activity has been designed for pharmacists.
How to Earn Credit
During the period February 18, 2020 to February 18, 2021, participants must
1) read the learning objectives and faculty disclosures; 2) view the
educational activity; and 3) complete the posttest and evaluation form
directly after the activity within a maximum of 60 days of participating in
the activity. To answer the questions, click on your selected choice for
each answer then proceed to the next question. Once completed, click on the
Grade Exam button at the bottom of the page. Your posttest will
automatically be graded. If you successfully complete the posttest (score
of 70% or higher), your statement of participation will be made available
immediately. Click on the View Statement of Participation link and print
the statement for your records. If you receive a score lower than 70%, you
will receive a message notifying you that you did not pass the posttest.
You will have 2 opportunities to pass the posttest. To receive Credit, you
must provide your date of birth and NABP number. All Credit information
will be uploaded into CPE monitor within 30 days.
GOAL
To educate pharmacists on the management of patients with HRS in order to
facilitate recognition of prognostic factors, selection of effective
pharmacologic treatments, and monitoring of outcomes.
EDUCATIONAL OBJECTIVES
Upon completion of this program, participants should be better able to:
- Recognize prognostic factors in patients presenting with HRS to predict
a potential outcome.
- Describe pharmacologic and non-pharmacologic treatment approaches to
patients with HRS.
- Choose the best pharmacologic treatment for HRS based on the published
evidence.
- Select appropriate dosage regimens and monitoring parameters for
pharmacologic agents used in HRS.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following
minimum requirements:
-
Operating System:
Windows 98 or higher & Macintosh 2.2 or higher
-
Internet Browser (Mac &/ Windows):
Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher,
Firefox 3.0.3 or higher & Opera 5 or higher
-
Broadband Internet connection:
Cable, High-speed DSL & any other medium that is internet
accessible
-
Peripherals:
Computer speakers or headphones
-
Monitor Screen Resolution:
320 x 480 or higher
-
Media Viewing Requirements:
Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer:
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of Postgraduate Healthcare
Education, LLC or Mallinckrodt. Participants have an implied responsibility
to use the newly acquired information to enhance patient outcomes and their
own professional development. The information presented in this activity is
not meant to serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patients' conditions, and possible contraindications on
dangers in use, (review of any applicable manufacturer's product
information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity
have made all reasonable efforts to ensure that all information contained
herein is accurate in accordance with the latest available scientific
knowledge at the time of acceptance for publication. However, because
information regarding drugs (their administration, dosages,
contraindications, adverse reactions, interactions, special warnings,
precautions, etc.) is subject to constant change, the reader is advised to
check the manufacturer's package insert for information concerning
recommended dosages and potential problems and cautions prior to dispensing
or administering the drug. Special precautions should be taken when a drug
is new, or highly toxic, or is unfamiliar to the dispenser or administrant.
This educational activity may contain discussion of published and/or
investigational uses of agents that are not approved by the U.S. Food and
Drug Administration (FDA). Neither the publisher nor sponsor promotes the
use of any agent outside of approved labeling. Statements made in this
activity have not been evaluated by the FDA.